Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Basic & Clinical Pharmacology & Toxicology

• Publication date

  2006-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/J.1742-7843.2006.PTO_437.XPMID 16867170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS

  2006cited by this paper
• Effect of rifampicin on the pharmacokinetics of pioglitazone.

  2006cited by this paper
• Prediction of drug metabolism and interactions on the basis of in vitro investigations.

  2005cited by this paper
• SELECTIVE INHIBITION OF HUMAN CYTOCHROME P4502C8 BY MONTELUKAST

  2005cited by this paper
• Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8

  2005cited by this paper
• Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.

  2005cited by this paper
• Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.

  2005cited by this paper
• Effect of Clopidogrel and Ticlopidine on Cytochrome P450 2B6 Activity as Measured by Bupropion Hydroxylation

  2005cited by this paper
• Effects of Gemfibrozil, Itraconazole, and Their Combination on the Pharmacokinetics of Pioglitazone

  2005cited by this paper
• The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.

  2005cited by this paper
• ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION

  2004cited by this paper
• Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil

  2004cited by this paper
• Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone

  2004cited by this paper
• Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

  2004cited by this paper
• Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide

  2004cited by this paper
• Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide

  2003cited by this paper
• Simultaneous determination of pioglitazone and its two active metabolites in human plasma by LC-MS/MS.

  2003cited by this paper
• Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

  2003cited by this paper
• Gemfibrozil greatly increases plasma concentrations of cerivastatin

  2002cited by this paper
• Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.

  2002cited by this paper
• Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.

  2002cited by this paper
• Pharmacokinetics and clinical efficacy of pioglitazone.

  2001cited by this paper
• Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.

  2001cited by this paper
• Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.

  2001cited by this paper
• The xenobiotic inhibitor profile of cytochrome P4502C8.

  2000cited by this paper
• Clinical pharmacokinetics of pioglitazone

  2000cited by this paper
• Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole.

  1999cited by this paper
• Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.

  1998cited by this paper
• Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.

  1997cited by this paper
• Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.

  1996cited by this paper
• Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9.

  1995cited by this paper
• Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

  1995cited by this paper
• Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.

  1995cited by this paper
• Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole

  1994cited by this paper
• Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes.

  1991cited by this paper
• Enhancement of type II substrate oxidation and of azo reduction in the isolated rat liver and in vitro by metyrapone.

  1973cited by this paper

• Comparative analysis of sex-based, vendor-based, and species differences in cytochrome P450 metabolism

  2026cites this paper
• Dietary Modulation of CYP3A4 and Its Impact on Statins and Antidiabetic Drugs: A Narrative Review

  2025influential citation
• An in-depth review of PPARγ modulators as anti-diabetes therapeutics

  2025cites this paper
• CYP2C8-Mediated Drug–Drug Interactions and the Factors Influencing the Interaction Magnitude

  2025cites this paper
• Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review

  2024cites this paper
• A web-based scoping review assessing the influence of smoking and smoking cessation on antidiabetic drug meabolism: implications for medication efficacy

  2024cites this paper
• Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential.

  2023cites this paper
• Phase I Metabolism of Pterostilbene, a Dietary Resveratrol Derivative: Metabolite Identification, Species Differences, Isozyme Contribution, and Further Bioactivation.

  2022cites this paper
• Management of diabetes mellitus in patients with cirrhosis: an overview and joint statement.

  2021cites this paper
• Effects of mulberry leaf extracts on activity and mRNA expression of five cytochrome P450 enzymes in rat

  2021cites this paper
• Increased DNA strand breaks and neoplastic transformation in human bladder cells treated with pioglitazone

  2021cites this paper
• In Silico Prediction of CYP2C8 Inhibition with Machine-Learning Methods.

  2021cites this paper
• Therapeutic Dilemma in personalized medicine.

  2021cites this paper
• Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective

  2020cites this paper
• Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer

  2020cites this paper
• Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.

  2019cites this paper
• Antidiabetic agents in patients with hepatic impairment

  2019cites this paper
• Identification of prognostic biomarkers for patients withhepatocellular carcinoma after hepatectomy

  2019cites this paper
• In vitro drug metabolism and pharmacokinetics of a novel thiazolidinedione derivative, a potential anticancer compound.

  2019cites this paper
• Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone.

  2019cites this paper
• The Role of Pharmacogenomics in Diabetes

  2019cites this paper
• Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole

  2019cites this paper
• In vitro enantioselective study of the toxicokinetic effects of chiral fungicide tebuconazole in human liver microsomes.

  2019cites this paper
• Exploring PTDH–P450BM3 Variants for the Synthesis of Drug Metabolites

  2018cites this paper
• Structure-function analysis of 1-hydroxypioglitazone, a major in vivo metabolite of the PPARγ agonist pioglitazone

  2018influential citation
• Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism

  2018cites this paper
• Although ABCC 8 1369 Ala and KCNJ 11 23 K variants

  2018cites this paper
• Bidirectional Pharmacokinetic Interaction Between Amodiaquine and Pioglitazone in Healthy Subjects

  2018cites this paper
• Zafirlukast and vincamine ameliorate tamoxifen‐induced oxidative stress and inflammation: Role of the JNK/ERK pathway

  2018cites this paper
• Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression

  2018cites this paper
• Synthesis of Heterobenzylic Fluorides

  2018cites this paper
• The utility of HepaRG cells for bioenergetic investigation and detection of drug-induced mitochondrial toxicity.

  2018cites this paper
• The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma

  2018cites this paper
• Structural basis of altered potency and efficacy displayed by a major in vivo metabolite of the anti-diabetic PPARγ drug pioglitazone

  2018cites this paper
• Thiazolidinediones and their drug interactions involving CYP enzymes

  2018cites this paper
• Expression and Activity of CYP2C8 and 2C9 in Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

  2018cites this paper
• Evaluation of pharmacokinetic interactions between bicyclol and co-administered drugs in rat and human liver microsomes in vitro and in rats in vivo

  2018cites this paper
• Pioglitazone for the treatment of Alzheimer’s disease

  2017cites this paper
• Effect of Cinnamomum cassia on the Pharmacokinetics and Pharmacodynamics of Pioglitazone.

  2017cites this paper
• University of Dundee CYP 2 C 8 and SLCO 1 B 1 variants and therapeutic response to thiazolidinediones in patients with type 2 diabetes

  2017cites this paper
• EDITORIAL: Spicing Up the Management of Type 2 Diabetes with Cinnamon.

  2017cites this paper
• Prediction of inter-individual variability on the pharmacokinetics of CYP2C8 substrates in human.

  2017cites this paper
• Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals

  2017cites this paper
• The effect of milk thistle (Silybum marianum) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes.

  2017cites this paper
• Assessment of preclinical pharmacokinetics and acute toxicity of pioglitazone and telmisartan combination

  2017cites this paper
• Distribution of CYP2C8 and CYP2C9 amino acid substitution alleles in South Indian diabetes patients: A genotypic and computational protein phenotype study

  2017cites this paper
• Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters

  2017cites this paper
• Simultaneous determination of amodiaquine and pioglitazone on dried blood spots (DBS) by HPLC–DAD and its usefulness in pharmacokinetic studies

  2017cites this paper
• Pharmacogenomics of Type 2 Diabetes Mellitus

  2017cites this paper
• Synergistic protection against acute flurothyl‐induced seizures by adjuvant treatment of the ketogenic diet with the type 2 diabetes drug pioglitazone

  2017cites this paper
• 22 Pharmacogenetics for T 2 DM and Anti-Diabetic Drugs

  2017cites this paper
• Pharmacogenetic Factors That Affect Drug Metabolism and Efficacy in Type 2 Diabetes Mellitus

  2017cites this paper
• Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes

  2017cites this paper
• Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics.

  2016cites this paper
• Pharmacogenetic studies update in type 2 diabetes mellitus.

  2016cites this paper
• A Convenient Late-Stage Fluorination of Pyridylic C-H Bonds with N-Fluorobenzenesulfonimide.

  2016cites this paper
• In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity

  2016influential citation
• Parkinson's Disease, Diabetes and Cognitive Impairment.

  2016cites this paper
• Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone

  2016influential citation
• Management of Diabetes in Liver Cirrhosis

  2016cites this paper
• Clarification of the Mechanism of Clopidogrel-Mediated Drug–Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information

  2016cites this paper
• Prevalence of the genetic mutation Cyp2c8*5 in selected ethnic groups in Southern Ghana

  2016cites this paper
• Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

  2016influential citation
• Clinically and pharmacologically relevant interactions of antidiabetic drugs

  2016cites this paper
• CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes

  2016cites this paper
• Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies

  2016cites this paper
• CYP2C8 and SLCO1B1 variants and therapeutic response to thiazolidinediones in patients with type 2 diabetes.

  2016cites this paper
• Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes

  2015cites this paper
• Systematic Evaluation of the Metabolism and Toxicity of Thiazolidinone and Imidazolidinone Heterocycles.

  2015cites this paper
• Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone

  2015influential citation
• Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries

  2015cites this paper
• Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8.

  2015cites this paper
• Drug‐drug interactions in pharmacologic management of gastroparesis

  2015cites this paper
• Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O -

  2015cites this paper
• Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?

  2015cites this paper
• Evaluation of herb-drug interactions in Nigeria with a focus on medicinal plants used in diabetes management

  2015cites this paper
• Drug Metabolizing Enzymes in Type II Diabetes and their Pharmacogenetics During Therapy of Anti-Diabetes Drugs.

  2015cites this paper
• Inhibitory effect of six herbal extracts on CYP2C8 enzyme activity in human liver microsomes

  2015influential citation
• Molecular and Protein characterization of Human cytochrome P450 expressed Recombinant E.Coli and its application in the synthesis of Tramadol metabolite

  2015cites this paper
• The treatment of diabetes mellitus of patients with chronic liver disease.

  2015cites this paper
• Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers.

  2015influential citation
• Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide

  2015cites this paper
• Pharmacogenomics of Oral Antidiabetic Drugs

  2014cites this paper
• The Effect of IGF2BP2 Gene Polymorphisms on Pioglitazone Response in Chinese Type 2 Diabetes Patients

  2014cites this paper
• Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans.

  2014cites this paper
• Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease

  2014cites this paper
• A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study.

  2014cites this paper
• Influence of Piperine on Pioglitazone Metabolism and Pk/Pd: Diabetes Mellitus

  2014cites this paper
• Mitochondrial Dysfunction as a Mechanism for Pioglitazone-Induced Injury toward HepG2 Cell Line

  2014cites this paper
• Role of CYP2C8 in the metabolism of montelukast and imatinib : Studies in vitro, in silico and in humans

  2014cites this paper
• Drugs as victims and perpetrators and the pharmacokinetic concept of maximum exposure

  2014cites this paper
• Influence of Piperine on Pioglitazone Metabolism and Pk/Pd: Diabetes

  2014cites this paper
• Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers.

  2013cites this paper
• Current clinical evidence on pioglitazone pharmacogenomics

  2013cites this paper
• Influence of CYP2C8*2 on the Pharmacokinetics of Pioglitazone in Healthy African‐American Volunteers

  2013cites this paper
• The Role of Pharmacogenetics in Drug Disposition and Response of Oral Glucose-Lowering Drugs

  2013cites this paper
• Comparative in vitro-in vivo correlation analysis with pioglitazone tablets

  2013cites this paper
• Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.

  2013cites this paper
• Influence of curcumin on pioglitazone metabolism and pk/pd: Diabetes Mellitus

  2013cites this paper
• The Role of Pharmacogenomics in Diabetes, HIV Infection, and Pain Management

  2013cites this paper